### 510(k) Summary K133009

APR 2 3 2014

## 1. 510(k) Owner's Information:

Name:

BMC Medical Co., Ltd.

Address:

Room 110 Tower A Fengyu Building, No. 115 Fucheng Road

Haidian, Beijing 100036, PEOPLE'S REPUBLIC OF CHINA

Phone:

0086-010-51663880-879

Fax:

0086-010-51663880-810

Contact person:

Jinjing

Date the summary was prepared [807.92(a)(1)]: September. 17, 2013

## 2. Applicant Device information:

Trade name:

BMC-NM Nasal Mask, BMC-NM2 Nasal Mask

BMC-FM Full Face Mask

Common name:

Vented Face Mask

Name/classification: Accessory to Non-continuous Ventilator

Product code:

**BZD** 

Regulation Number: 21CFR 868.5905

Device Class: II

## 3. Predicate Device

## 3.1 Predicate Device of Nasal Mask BMC-NM and BMC-NM2

Product name: ComfortGel<sup>TM</sup> (K092835) Manufacturer: RESPIRONICS

**Product name:** Mirage Activa<sup>TM</sup> (K030798)

Manufacturer: Resmed

**Product Code: BZD** 

**Intended Use:** 

## Mirage ActivaTM Mask (K030798):

Mirage ActivaTM mask is an accessory to a non-continuous ventilator (respirator) intended for single-patient use for adult patients prescribed continuous positive airway pressure (CPAP) and bi-level therapy in hospital, clinic, and home environments.

ComfortGel<sup>TM</sup>(K092835):

Report No.: BMC-TF (FDA)-STA-01

The ComfortGel Blue Nasal Mask is intended to provide an interface for application of CPAP or bi-level therapy to patients. The mask is for single patient use in the home or multi-patient use in the hospital/institutional environment. The mask is to be used by patients (>66lbs/30kg) for whom CPAP or bi-level therapy has been prescribed.

## 3.2 Predicate Device of BMC-FM full face mask

Product name: Mirage Quattro (K113127) Manufacturer: Resmed

**Product Code: BZD** 

. **.** .

### Intended Use:

The Mirage Quattro channels airflow noninvasively to a patient from a positive airway pressure device such as a continuous positive airway pressure (CPAP) or bilevel system.

The Mirage Quattro is to be used by adult patients (>66lbs / >30kg) for whom positive airway pressure has been prescribed.

The Mirage Quattro is intended for single patient re-use in the home environment and/or multi-patient reuse in the hospital/institutional environment.

## 4. Device Description

## 4.1 BMC-NM and BMC-NM2 Nasal Mask

BMC-NM and BMC-NM2 Nasal Masks are interfaces such that airflow from a positive pressure source is directed to the patient's nose. The masks are held in place with adjustable headgear that straps the mask to the face. BMC-NM and BMC-NM2 Nasal Masks have hard plastic body and softer silicone seal that touches the face and include a pad that rests on the forehead. The seal may inflate once the machine is turned on so the straps do not need to be too tight.

The BMC-NM and BMC-NM2 are safe when used under the conditions and purposes intended as indicated in the labeling provided with the product.

The BMC-NM and BMC-NM2 are prescription devices supplied non-sterile.

## 4.2 BMC-FM Full Face Mask

BMC-FM full face mask is interfaces such that airflow from a positive pressure source is directed to the patient's mouth and nose. The masks are held in place with adjustable headgear that straps the mask to the face. BMC-FM Full face Mask has plastic body and softer silicone seal that touches the face and include an adjustable pad that rests on the forehead. The seal may inflate once the machine is turned on so the straps do not need to be too tight.

The BMC-FM is safe when used under the conditions and purposes intended as indicated in the labeling provided with the product.

The BMC-FM is prescription device supplied non-sterile.

## 5. Statement of intended use

The BMC-NM, BMC-NM2 Nasal Mask and BMC-FM full face mask channel airflow noninvasively to a patient from a positive airway pressure device such as a continuous positive airway pressure (CPAP) or Bi-level system.

The BMC-NM, BMC-NM2 Nasal Mask and BMC-FM full face mask are:

- To be used by adult patients (>66lbs / >30kg) for whom positive airway pressure has been prescribed.
- Intended for single-patient reuse in home environment and multi-patient re-use in the hospital/institutional environment.

Premarket Notification 510(k) Submission-510(k) Summary Report No.: BMC-TF (FDA)-STA

## 6. Technical Comparison to the predicate device

## 6.1 Comparison table1 (Nasal mask to its predicate device)

	Applic	Applicant Device	Predicated Device	)evice
Comparison Elements	BMC-NM	BMC-NM2	ComfortGeI <sup>TM</sup> Nasal Mask (K092835)	Mirage Activa <sup>TM</sup> (K030798)
Device name	Nasal mask	Nasal mask	Nasal mask	Nasal mask
Classification name	Accessory to Non-continuous Ventilator	Accessory to Non-continuous Ventilator	Accessory to Non-continuous Ventilator	Accessory to Non-continuous Ventilator
Product code	BZD	BZD	BZD	BZD
Comparison statement: T	he applicant devices a	are substantially equival	Comparison statement: The applicant devices are substantially equivalent to the predicate devices.	
Intended Use	The BMC-NM and BMC-N channel airflow noninvasiv from a positive airway pres as a continuous positive air (CPAP) or Bi-level system. The BMC-NM and BMC-N are:  To be used by adult pare:  To be used by adult pare:  Intended for single-pat home environment and mu in the hospital/institutional	The BMC-NM and BMC-NM2 Nasal Mask channel airflow noninvasively to a patient from a positive airway pressure device such as a continuous positive airway pressure (CPAP) or Bi-level system.  The BMC-NM and BMC-NM2 Nasal Mask are:  To be used by adult patients (>66lbs / >30kg) for whom positive airway pressure has been prescribed.  Intended for single-patient reuse in home environment and multi-patient re-use in the hospital/institutional environment.	The ComfortGel Blue Nasal Mask is intended to provide an interface for application of CPAP or bi-level therapy to patients. The mask is for single patient use in the home or multi-patient use in the hospital/institutional environment. The mask is to be used by patients (>66lbs/30kg) for whom CPAP or bi-level therapy has been prescribed.	Mirage Activa <sup>TM</sup> mask is an accessory to a non-continuous ventilator (respirator) intended for single-patient use for adult patients prescribed continuous positive airway pressure (CPAP) and bi-level therapy in hospital, clinic, and home environments.
Indications for use	The BMC-NM and I channel airflow noni	The BMC-NM and BMC-NM2 Nasal Mask channel airflow noninvasively to a patient	The ComfortGel Blue Nasal Mask is intended to provide an interface	Mirage Activa <sup>TM</sup> mask is an accessory to a

Premarket Notification 510(k) Submission-510(k) Summary Report No.: BMC-TF (FDA)-STA

	Applica	Applicant Device	Predicated Device	Device
Comparison Elements	BMC-NM	BMC-NM2	ComfortGel <sup>TM</sup> Nasal Mask (K092835)	Mirage Activa <sup>TM</sup> (K030798)
,	from a positive airway pressure device si as a continuous positive airway pressure	from a positive airway pressure device such as a continuous positive airway pressure	for application of CPAP or bi-level therapy to patients. The mask is for	non-continuous ventilator (respirator) intended for
	(CPAP) or Bi-level system.  The BMC-NM and BMC-NM2 Nasal	stem. BMC-NM2 Nasal	single patient use in the nome or multi-patient use in the	single-patient use for adult patients prescribed
,	Mask are:  To be used by ad	fask are: To be used by adult natients (>66lbs /	hospital/institutional environment. The mask is to be used by patients	continuous positive airway pressure (CPAP) and bi-level
	>30kg) for whom po	>30kg) for whom positive airway pressure	(>66lbs/30kg) for whom CPAP or hi-level therapy has been	
	nas oeen prescrioed.  • Intended for single-patient reuse in	le-patient reuse in	ed.	
	home environment ar	home environment and multi-patient re-use		
	in the hospital/institutional environment.	nonal environment.		
Target population	Adult (>661bs / >30kg)	3)	Adult (>66lbs/30kg)	Adult
Environment of use	home or hospital/ins	home or hospital/institutional environment	home or hospital/institutional	hospital/clinic and home
			CIIVIIUIIIICIII	CIIVIIOIIIIICIII
Patient usage type	Single-patient reuse in home en and multi-patient re-use hospital/institutional environment.	Single-patient reuse in home environment and multi-patient re-use in the hospital/institutional environment.	Single-patient reuse in home environment and multi-patient re-use in the hospital/institutional environment.	Single patient reuse
Anatomical site	Nose		Nose	Nose
Provided sterile or non-sterile	Not sterile		Not sterile	Not sterile
Comparison Statement	The applicant devic	es are substantially equi	The applicant devices are substantially equivalent to the predicate devices.	
Design	Nasal interface and headgear	eadgear	Nasal interface and headgear	Nasal interface and headgear
Number of mask size	Three-small, medium, and large	, and large	Three-small, medium, and large	Four-small, medium, large,

Premarket Notification 510(k) Submission-510(k) Summary Report No.: BMC-TF (FDA)-STA

		Applicar	cant Device	Predicated Device	Device
Comp	Comparison Elements	BMC-NM	BMC-NM2	ComfortGel <sup>TM</sup> Nasal Mask (K092835)	Mirage Activa <sup>TM</sup> (K030798)
					large and wide
Patien	Patient circuit connection	22mm entrainment valve elbow	lve elbow	22mm entrainment valve elbow	22mm entrainment valve elbow
Comp	Comparison Statement	The applicant device	s are substantially equi	The applicant devices are substantially equivalent to the predicate devices.	
	Therapy Pressure range	4 to 3	to 30 hPa	4 to 30 hPa	4-20hPa
	Intentional leak	4hPa=19L/min	4hPa=20L/min	4hPa=15L/min	4hPa=19L/min
		12hPa=34/min	12hPa=40/min	12hPa=31/min	12hPa=34L/min
suoj		20hPa=50L/min	20hPa=51L/min	20hPa≒34L/min	20hPa=45L/min
ificati		30hPa=68L/min	30hPa=72L/min	30hPa=46L/min	
oədS	Dead space (large size)	145ml	135ml	142.6ml	145ml
əəiv	Resistance/	0.2 hPa at 50L/min	0.2 hPa at 50 L/min	0.1 hPa at 50L/min	0.3 hPa at 50L/min
De	Pressure Drop	0.7 hPa at 100L/min	0.5 hPa at 100 L/min	0.25 hPa at 100L/min	0.9 hPa at 100L/min
	Operating	5 to 40°C		5 to 40°C	5 to 40°C
	environment	10% to 93%	relative humidity,	15% to 95% relative humidity,	15% to 95% relative
		non-condensing		non-condensing	humidity, non-condensing

7 / 13

Premarket Notification 510(k) Submission-510(k) Summary Report No.: BMC-TF (FDA)-STA

		Applica	icant Device	Predic	Predicated Device	
Com	Comparison Elements	BMC-NM	BMC-NM2	ComfortGel <sup>TM</sup> Nasal N (K092835)	Mask Mirage Activa TM (K030798)	10798)
	Storage environment	-20 to +55°C 10% to '93% non-condensing.	relative humidity,	-20 to +60°C up to 95% relative humidity, non-condensing	-20 to +60°C dity, up to 95% relative humidity, non-condensing	midity,
Com	Comparison Statement	The applicant device	s have similar specifica	The applicant devices have similar specifications as the predicate devices.		
		Polycarbonate		Polycarbonate	Polycarbonate	
		Silicon		Silicon	Silicon	
Main	Main materials	Nylon &spandex Fabric	ric	GUrethane gel/EVA Urethane film	"Breathoprene" fabric	
				UBL, Urethane Foam, and Lycra	.a	
Com	Comparison Statement	The applicants devic	es have similar materia	The applicants devices have similar materials with the predicate devices.	,	
ement	Performance testing	Tested to determine characteristic, dead	the pressure-flow space (CO2	leak, pressure eathing, dead	Tested to det pressure-flow c dead space	e the teristic,
ola Via		re-breathing), and flov	flow impedance.	testing test.	re-breathing), and impedance.	How
de2	Clinical testing	None clinical testing needed	pepead	None clinical testing needed		
Hmr	Human factors	Compliance with FDA	FDA guidance	Compliance with FDA guidance		
Con	Comparison Statement	The applicant device	es are substantially equi	The applicant devices are substantially equivalent to the predicate devices.		
Lab	Label and Labeling	Compliance with FD/	FDA guidance	Compliance with FDA guidance		

Premarket Notification 510(k) Submission-510(k) Summary Report No.: BMC-TF (FDA)-STA

	Applic	plicant Device		Pre	redicated Device	Device
Comparison Elements	BMC-NM	BMC-NM2	ComfortGeI <sup>TM</sup> Nasal Mask (K092835)	Nasal	Mask	Mirage Activa <sup>TM</sup> (K030798)
Comparison Statement	The applicant devic	evices are substantially equivalent to the predicate devices.	uivalent to the pred	icate devi	ces.	

# 6.2 Comparison table 2 (Full face mask to Mirage Quattro (K113127))

Comparison Flements	Applicant Device	Predicated Device
	BMC-FM	Mirage Quattro TM (K113127)
Device name	Full Face Mask	Full Face Mask
Classification name	Accessory to Non-continuous Ventilator	Accessory to Non-continuous Ventilator
Product code	BZD	BZD
Comparison statement: The applicant device	ant device is substantially equivalent to the predicate device.	cate device.
Intended Use	The BMC-FM full face mask channel airflow noninvasively to a patient from a positive airway pressure device such as a continuous positive airway pressure (CPAP) or Bi-level system.  The BMC-FM full face mask are:  The full face mask is:  To be used by adult patients (>66lbs / >30kg) for whom positive airway pressure has been prescribed.  Intended for single-patient reuse in home environment and multi-patient re-use in the hospital/institutional environment.	The Mirage Quattro channels airflow noninvasively to a patient from a positive airway pressure device such as a continuous positive airway pressure (CPAP) or bilevel system.  The Mirage Quattro is to be used by adult patients (>66 lb / 30 kg) for whom positive airway pressure has been prescribed.  The Mirage Quattro is intended for single-patient re-use in the home environment and multipatient re-use in the hospital/institutional environment.

Premarket Notification 510(k) Submission-510(k) Summary Report No.: BMC-TF (FDA)-STA

Comparison Flements	Applicant Device	Predicated Device
	BMC-FM	Mirage Quattro <sup>TM</sup> (K113127)
Indications for use	The BMC-FM full face mask channels airflow noninvasively to a patient from a positive airway pressure device such as a continuous positive airway pressure (CPAP) or Bi-level system.  The BMC-FM full face mask are:  The full face mask is:  To be used by adult patients (>66lbs / >30kg) for whom positive airway pressure has been prescribed.  Intended for single-patient reuse in home environment and multi-patient re-use in the hospital/institutional environment.	The Mirage Quattro channels airflow noninvasively to a patient from a positive airway pressure device such as a continuous positive airway pressure (CPAP) or bilevel system.  The Mirage Quattro is to be used by adult patients (>66 lb / 30 kg) for whom positive airway pressure has been prescribed.  The Mirage Quattro is intended for single-patient re-use in the home environment and multipatient re-use in the hospital/institutional environment.
Target population	Adult (>66lbs / >30kg)	Adult (>66lbs/30kg)
Environment of use	Home environment and the hospital/institutional environment	Home environment and the hospital/institutional environment
Patient usage type	single-patient reuse in home environment and multi-patient re-use in the hospital/institutional environment	single-patient re-use in the home environment and multi-patient re-use in the hospital/institutional environment
Anatomical site	Nose and mouth	Nose and mouth
Provided sterile or non-sterile	Not sterile	Not sterile
Comparison Statement	The applicant device is substantially equivalent to the predicate device.	to the predicate device.
Design	face interface and headgear	face interface and headgear
Number of mask size	Three-small, medium, and large	Four -Extra small, small, medium, and large

Premarket Notification 510(k) Submission-510(k) Summary Report No.: BMC-TF (FDA)-STA

	portion pine it (1511) 5111		
J.	Comparison Flements	Applicant Device	Predicated Device
		BMC-FM	Mirage Quattro <sup>TM</sup> (K113127)
Patie	Patient circuit connection	22mm entrainment valve elbow	22mm entrainment valve elbow
Com	Comparison Statement	The applicant device is substantially equivalent to the predicate device.	to the predicate device.
	Therapy Pressure range	4 to 30 hPa	4 to 40 hPa
	Intentional leak	4 cm H2O =23 L/min	4 cm H2O =22 L/min
		8 cm H2O =33 L/min	8 cm H2O =32 L/min
		12 cm H2O =43 L/min	12 cm H2O =41 L/min
		16 cm H2O =49 L/min	16 cm H2O =48 L/min
		20  cm H 20 = 54  L/min	20 cm H2O =54 L/min
		25 cm H2O =63 L/min	24cm H2O =60L/min
•		30 cm H2O =69 L/min	28cm H2O =66L/min
sue			32cm H2O =72L/min
oita			36cm H2O =72L/min
offi			38cm H2O =77L/min
			40cm H2O =82 L/min
I <sub>S</sub>	Dead space (large size)	246mL	242 mL
əəiv	Resistance/	at $50L/min$ : 0.2 cm $H_2O$	at 50 L/min: 0.1 cm H <sub>2</sub> O
De	Pressure Drop	at $100L/min$ : 0.3 cm $H_2O$	at 100 L/min: 0.4 cm H <sub>2</sub> O
	Inspiratory and expiratory		
	resistance (with Anti	Anti Inspiration at 50 L/min 1.0 cm H2O	Inspiration at 50 L/min 0.8 cm H2O
	Asphyxia Valve open to	Expiration at 50 L/min 1.2 cm H2O	Expiration at 50 L/min 0.8 cm H2O
	atmosphere)		
	one antimo mitomono	5 to 40°C	5°C to 40°C
	Operating citynomicine	10% to 93 % relative humidity non-condensing	15% to 95% relative humidity non-condensing

Premarket Notification 510(k) Submission-510(k) Summary Report No.: BMC-TF (FDA)-STA

ŭ	omparison	Comparison Elements		Applicant Device	Predicated Device
<u> </u>				BMC-FM	Mirage Quattro TM (K113127)
	Storage	ge and	transport	-20 to +55°C	-20 to +60°C
	envir	environment		10% to 93% relative humidity, non-condensing	10% to 95% relative humidity, non-condensing
<u>ၓ</u>	omparison	Comparison Statement		The applicant device has similar specifications as the predicate device.	as the predicate device.
				Polycarbonate	Polycarbonate
i	,			Silicon	Silicon
Σ	Materials			Nylon &spandex Fabric	Fabric/Nyton
ర	omparison	Comparison Statement		The applicants device has similar materials with the predicate devices.	h the predicate devices.
уjə	зиэ	Performance testing	gui	Testing according to ISO 17510-2	Testing according to ISO 17510-2
de2	mələ	Clinical testing		None clinical testing needed	None clinical testing needed
ŭ	omparisor	Comparison Statement		The applicant device is substantially equivalent to the predicate device.	to the predicate device.
Τ	Label and Labeling	abeling		Compliance with FDA guidance	Compliance with FDA guidance
ŭ	omparisor	Comparison Statement		The applicant device is substantially equivalent to the predicate device.	to the predicate device.

## 7. Safety element

## 7.1 Biocompatibility tests

Model	BMC-NM BMC-NM2	BMC-NM2	BMC-FM	Nasal pillow mask(K112271)
	Polycar	olycarbonate	Polycarbonate	Polycarbonate
Materials	Silic	Silicon	Silicon	Silicon
	Nylon &spa	dylon &spandex Fabric	Nylon &spandex Fabric	Nylon &spandex Fabric

The materials used in BMC-NM, BMC-NM2 and BMC-FM in this submission are exactly the same as those materials used in nasal pillow mask(K112271) and not through cytotoxicity, sensitization and irritation, which were not performed in this submission.

Model	<b>BMC-NM</b>	BMC-NM BMC-NM2	BMC-FM
Contact Type	c Tissue c	Fissue contacting	Tissue contacting
duration of contact	Permane	ermanent contact	Permanent contact

## 7.2 Nonclinical tests

To verify the substantial equivalence claim, the BMC-NM, BMC-NM2 were performance bench tested against the Mirage Activa<sup>TM</sup> Mask, (K030798) and ComfortGel<sup>TM</sup> (K092835), the BMC-FM was performance bench tested against the Mirage Quattro (K113127).

the passive exhalation port flow, the resistance to flow and the deadspace for both BMC-NM and BMC-NM2 are substantial equivalence with The bench testing includes performance test, drop test, damp heat test and disinfection validation test. In the performance tests, it turns out that ComfortGel<sup>TM</sup> Nasal Mask and Mirage Activa TM . In terms of BMC-FM, the passive exhalation port flow, the resistance to flow and the deadspace is substantial equivalence with Mirage QuattroTM.

The drop tests show that BMC-NM, BMC-NM2, BMC-FM(Fully assembled and without packaging) and the carton packaging are able to withstand routine handling. The damp heat tests state that the BMC-NM, BMC-NM2 and BMC-FM withstand damp heat test with no damage to mask components, and

Υ. .

Premarket Notification 510(k) Submission-510(k) Summary Report No.: BMC-TF (FDA)-STA

without noticeable degradation of materials or negative impact of component form, fit or function.

The disinfection validation tests show that the BMC-NM, BMC-NM2,BMC-FM may be either thermally or chemically disinfected/reprocessed thirty (30) times with no damage to mask components, and without noticeable degradation of materials or negative impact of component form, fit or function.

In a conclusion, The test reports show that the BMC-NM Nasal Mask, BMC-NM2 Nasal Mask and BMC-FM Full Face Mask are substantially equivalent to the predicate device.

## 7.3 Clinical test

Use of face masks with CPAP or bi-level therapy is proven technology and is well accepted by the medical community. The Bench testing demonstrates that the devices perform in an equivalent manner or that they are substantially equivalent to the predicate devices.

## 8. Conclusion:

The conclusion drawn from these tests is that the performance of the nasal mask BMC-NM, BMC-NM2 and full face mask BMC-FM are substantially equivalent to the predicate devices.



Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-0002

April 23, 2014

BMC Medical Co., Ltd.
Ms. Jinjing
5/F Main Building, No.19 Gucheng Street West
Shijingshan, 100043 Beijing,
PEOPLE'S REPUBLIC OF CHINA

Re: K133009

Trade/Device Name: Nasal mask BMC-NM, BMC-NM2 and Full face mask BMC-FM

Regulation Number: 21 CFR 868.5905 Regulation Name: Vented Face Mask

Regulatory Class: Class II Product Code: BZD Dated: March 20, 2014 Received: March 24, 2014

Dear Ms. Jinjin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm">http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm</a>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm">http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm</a> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm">http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm</a>.

Sincerely yours,

Digitally signed by Richard C. Chapman Date: 2014.04.23 14:23:55 -04'00'

for
Erin I. Keith
Acting Division Director
Division of General Hospital, Respiratory,
Anesthesiology Infectious Control, and Dental
Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

**Enclosure** 

## DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

## Indiaationa for Hos

Form Approved: OMB No. 0910-0120 Expiration Date: December 31, 2013

See PRA Statement on last page.
c channel airflow noninvasively to a patient from a positive (CPAP) or Bi-level system.
k are: way pressure has been prescribed. tient re-use in the hospital/institutional environment.
/
Over-The-Counter Use (21 CFR 801 Subpart C)
ONTINUE ON A SEPARATE PAGE IF NEEDED.
SE ONLY



Digitally signed by James J. Lee DN c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=James J. Lee, 0.9.2342 19200300.100.1.1=2000954859

Date: 2014.04.23 13:35:24 -04'00'

This section applies only to requirements of the Paperwork Reduction Act of 1995.

## \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."